Some information on this page may be available only to Healthcare Professionals. Please


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The biotech giant offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also a global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front-runner in diabetes management.​

Founded in 1896, the company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than 30 medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. The Roche Group, headquartered in Basel, Switzerland, has had a presence in Singapore since 1973.



Roche Singapore Pte Ltd

1 Paya Lebar Link, #09-03 PLQ 1, Paya Lebar Quarter, Singapore 408533​

Key Trials

3 trials shown



Official trial

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

4 February 2020

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:- - Arm A: Tiragolumab plus atezolizumab and CE - Arm B: Placebo plus atezolizumab and CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).

Trial number: NCT04256421 Study type: immunotherapy, chemotherapy Trial phase: 3 Overall status: Recruiting


Official trial

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

29 January 2020

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.

Trial number: NCT04191499 Study type: hormonal, targeted Trial phase: 2, 3 Overall status: Recruiting


Official trial

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

31 December 2019

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

Trial number: NCT04102098 Study type: immunotherapy, targeted Trial phase: 3 Overall status: Recruiting